HONG KONG, Sept. 28, 2023 /PRNewswire/ The journey of BIOHK2023 began with an unforgettable opening ceremony on day one, welcoming the Nobel Trust Foundation, Dr. Michael Nobel and delivering a noteworthy speech by Mr. Peter Nobel. BIOHK had the privilege of hosting distinguished doctors, professors, C-level executives, and prominent industry leaders, from around the world uniting together under one roof in Hong Kong, sharing their valuable insights to the biotechnology community. Thank you to the Sponsors & Supporting Organizations of BIOHK2023 for creating a truly memorable event. We were honored to have insightful keynote speeches delivered by renowned individuals, including: Mr. CY Leung, Vice Chairman of CPPCC Dr. Bruce Beutler, Nobel Laureate Ambassador George Hara, Group Chairman and CEO of DEFTA Partners Professor Yi Rao, President of Capital Medical University Sir Jonathan Symonds, Chair of GSK BIOHK2023 also welcomed over 50 innovative companies from across the globe to
nikkei.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nikkei.com Daily Mail and Mail on Sunday newspapers.
Credit: Metronom Health
Chinese medical device innovation hub Dinova Medtech and US-based medical device company Metronom Health have established a joint venture to develop and sell a continuous glucose monitoring system in China.
WHY IT MATTERS
Traditional fingerstick glucose meters can only provide information about intermittent glucose levels and the pain that comes with finger pricking can potentially reduce patients adherence. By inserting a sensor into the subcutaneous tissue along with a transmitter that sends the data to a smart device, CGMs can provide continuous glucose information to detect glycemic variability.
According to a press release, Metronom Health has developed a minimally invasive CGM system that uses proprietary Opto-enzymatic technology – in contrast to most CGMs that use electrochemical technology – to capture both high and low ranges of a patient s glucose profile. The company claims that this will be done with high accuracy and also asserts th